As a high-tech pharmaceutical enterprise integrating R&D, production and domestic and international sales, Nanjing Hengsheng Pharmaceutical Co., Ltd. is a state-recognized high-tech enterprise; Hengsheng Pharmaceutical is a leader in drug research and development industry with "efficient, high-quality and rapid research and development capability", and owns the provincial-level enterprise technology center, the provincial-level polysaccharide and iron composite drug engineering technology research center, the provincial-level chronic nephrology drug engineering research center. It has provincial enterprise technology center, provincial polysaccharide iron complex drug engineering technology research center, provincial chronic kidney drug engineering research center, and has successfully developed more than forty national new drugs, of which nearly thirty new drugs are the first to obtain new drug certificates and production approvals in China, filling the gaps in the domestic market; the core projects of the research and development have been listed in the national, provincial and municipal scientific and technological development plan for many times.
The company has become a leader in this field with a steady increase in industrial scale, and has been recognized as one of the top 2020 companies in the industry.
Tripod 蘚素 "夕南京市瞪羚企业。 The manufacturing center of Hang Seng Pharmaceutical is equipped with various facilities with innovative and international standards, and has a scientific and strict production and quality management system, which has passed the new GMP certification, IS09001 quality system certification, F014001 environmental management system certification, ISO18001 occupational health and safety management system certification, one-time Runcie, Peru and other countries CGMP certification and on-site auditing. The company is in a leading position among similar enterprises. Focusing on nephrology and cardiovascular and cerebrovascular fields, Hang Seng Pharmaceutical is committed to providing customers with high-quality pharmaceutical products and specialized services. The core products of the company, such as iron sucrose injection, ibandronate injection, resorcinol injection and sevelamer carbonate tablets, are all independently researched and developed, and they are listed in the market for the first time in China. The production technology and process are at the leading level in China, and the production and sales volume rank the top in China, and the quality of the products meets or exceeds the level of the same industry, and the leading products, such as Compound Dilong Capsules and Cardiac Painkillers Capsules, are the "Exclusive Protected Varieties of Chinese Medicines". The leading products are "Exclusive Protected Variety of Chinese Medicine".
Positioning "specialization, internationalization", after nearly 15 years of layout of export business, the company has gradually stabilized the fence and built a moat. High-standard production system in line with GMP requirements has been established around the high-end export market; at the same time, the company has accumulated experience in overseas registration technology and established mature sales channels and resources in overseas markets, which constitutes a competitive barrier for the company in overseas markets, and its products are exported to Russia, Mexico, the Philippines and other nearly 30 countries and regions.
Adhering to the development philosophy of "technology first, quality supreme, leading standards, scientific management", Hang Seng Pharmaceuticals is making every effort to build a leading enterprise of "specialized iron and renal brand products" with technological innovation as the forerunner, featured products as the core, knowledge-based marketing as the gripping hand, and reaching the standards of developed countries as the goal. brand products".
